PMID- 25876607
OWN - NLM
STAT- MEDLINE
DCOM- 20200210
LR  - 20200210
IS  - 1557-1246 (Electronic)
IS  - 1087-0547 (Linking)
VI  - 23
IP  - 1
DP  - 2019 Jan
TI  - What Is a Clinically Relevant Improvement in Quality of Life in Adults With ADHD?
PG  - 65-75
LID - 10.1177/1087054715580395 [doi]
AB  - OBJECTIVE: To estimate a minimal clinically important difference (MCID) on the 
      adult ADHD Quality of Life (AAQoL) scale. METHOD: The MCID was determined from 
      data from short-term ( N = 537) and long-term ( N = 440), placebo-controlled 
      atomoxetine trials in adults with ADHD. For the anchor-based approach, change in 
      clinician-rated Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) scores was 
      used to derive MCID. For the distribution-based approach, baseline-to-endpoint 
      mean ( SD) changes in AAQoL scores corresponding to 0.5 SD were computed. 
      RESULTS: The MCID was similar (approximately 8-point difference) between the 
      short-term and the long-term treatment groups when either the anchor-based or 
      distribution-based approach was used. CONCLUSION: These results suggest that 
      approximately 8 points in the change from baseline on the AAQoL is a MCID.
FAU - Tanaka, Yoko
AU  - Tanaka Y
AD  - 1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
FAU - Brod, Meryl
AU  - Brod M
AD  - 2 The Brod Group, Mill Valley, CA, USA.
FAU - Lane, Jeannine R
AU  - Lane JR
AD  - 3 inVentiv Health, Indianapolis, IN, USA.
FAU - Upadhyaya, Himanshu
AU  - Upadhyaya H
AD  - 1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150415
PL  - United States
TA  - J Atten Disord
JT  - Journal of attention disorders
JID - 9615686
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 57WVB6I2W0 (Atomoxetine Hydrochloride)
SB  - IM
MH  - Adolescent
MH  - Adrenergic Uptake Inhibitors/therapeutic use
MH  - Adult
MH  - Aged
MH  - Atomoxetine Hydrochloride/therapeutic use
MH  - Attention Deficit Disorder with Hyperactivity/drug therapy/*psychology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - ADHD
OT  - atomoxetine
OT  - attention deficit/hyperactivity disorder
OT  - quality of life
EDAT- 2015/04/17 06:00
MHDA- 2020/02/11 06:00
CRDT- 2015/04/17 06:00
PHST- 2015/04/17 06:00 [pubmed]
PHST- 2020/02/11 06:00 [medline]
PHST- 2015/04/17 06:00 [entrez]
AID - 1087054715580395 [pii]
AID - 10.1177/1087054715580395 [doi]
PST - ppublish
SO  - J Atten Disord. 2019 Jan;23(1):65-75. doi: 10.1177/1087054715580395. Epub 2015 
      Apr 15.